- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01300611
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation (USBTXA127CBT)
7. Dezember 2020 aktualisiert von: Tarix Pharmaceuticals
Phase I Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Adults Undergoing Double Cord Blood Transplantation
The purpose of this study is to evaluate the effect of TXA127 on neutrophil and platelet counts in adult patients who have undergone a double cord blood transplant.
The study will also evaluate the effect of TXA127 on chemotherapy-induced mucositis, an inflammation of the mucous membranes in the digestive tract (mouth to anus) and immune reconstitution which helps patients fight infections.
For patients undergoing CBT, both neutrophil and platelet normalization and immune reconstitution can be delayed.
TXA127 has shown to be well tolerated by patients and appears to induce a rapid production of neutrophils and platelets in the bloodstream as well as increase the immune system components.
It has also been shown to reduce the severity of chemotherapy-induced mucositis.
Studienübersicht
Status
Beendet
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Cord blood as a hematopoietic stem cell source has multiple advantages.
Cord blood is normally discarded at birth and can easily be collected and stored.
Availability of numerous CB banks has resulted in genetically diverse CB units including those from non-Caucasians.
Once a suitable CB unit is located, confirmatory typing can be quickly performed and a donor unit can be shipped to the transplant center.
Furthermore, because a CB graft results in a lower incidence of graft-versus-host-disease, one or two antigen-mismatched units are acceptable for transplantation.
Despite these advantages, CB has a significant drawback which is that the number of hematopoietic stem cells obtained from a unit of CB is significantly lower than from a bone marrow (BM) harvest or peripheral blood stem cell (PBSC) harvest.
Both engraftment and immune reconstitution are delayed in patients undergoing CB transplant.
TXA127 is pharmaceutically-formulated angiotensin 1-7, a non-hypertensive derivative of angiotensin II (which contains the 8th amino acid conferring receptor binding to blood pressure receptors).
TXA127 has multilineage effects on hematopoietic progenitors in vitro and in vivo.
The hematopoietic properties demonstrated in preclinical and clinical studies support the investigation of TXA127 to reduce time to neutrophil and platelet engraftment following transfusion of limited number of CD34+ cells.
Studientyp
Interventionell
Einschreibung (Voraussichtlich)
20
Phase
- Phase 1
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- MD Anderson Cancer Center
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre bis 60 Jahre (Erwachsene)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Subjects with Acute Myelogenous Leukemia (AML) past first remission, in first or subsequent relapse, induction failure, or in first remission with high-risk for relapse (with high-risk cytogenetics or presence of flt3 mutation or secondary leukemia from prior chemotherapy)
- Myelodysplastic Syndrome or Myelofibrosis of intermediate or high-risk
- Acute Lymphoblastic Leukemia (ALL): Induction failure, fist complete remission with Philadelphia chromosome or translocation (4:11), hypodiploidy and or evidence of minimal residual disease by flow cytometry, second or third complete remission or second relapse
- Chronic Myelocytic leukemia (CML): Second chronic phase or accelerated phase
- Non-Hodgkin's Lymphoma (NHL): Induction failures, second or third complete remission or relapse
- Hodgkin's Lymphoma (HL): Induction failures, second or third complete remission or relapse
- Chronic Lymphocytic leukemia (CLL): Progressive disease following standard therapy
- Other hematologic malignancies which meet investigational site standards for cord blood transplant
- Subjects must be at least 18 years of age
- Subjects must have ECOG status of ≤ 2
- Subjects with bone marrow blasts ≤ 10%
- Subjects must have adequate major organ function
- Male and Female Subjects capable of reproduction must agree to use contraceptive methods during the course of the study and for 2 months following the last administration of study drug
- Cord blood requirements: a) Unrelated CB will be used as a source of hematopoietic support if a 7/8 or 8/8 related or 8/8 unrelated bone marrow donor is not available, or if the tempo of the subject's disease dictates it is not in the subject's best interest to wait for an unrelated marrow donor to be procured. b) Subjects must have two CB units available which are matched with the subject at 4/6, 5/6, or 6/6 HLA class I (serological) and II (molecular) antigens. Each unit must contain at least 1 x 10^7 total nucleated cells/kg recipient body weight (pre-thaw).
Exclusion Criteria:
- Subjects who received antineoplastic treatment including chemotherapy, immunotherapy and radiation therapy ≤ 2 weeks prior to Screening Period
- Subjects who underwent prior total body irradiation
- Subjects who received prior allogeneic hematopoietic cell transplants
- Subjects seropositive for HIV, Hepatitis B or Hepatitis C
- Female subjects who are pregnant or breastfeeding
- Subjects who have received an investigational drug within 30 days of projected first administration of study drug (Day 0)
- Subjects with current alcohol use, illicit drug use, or any other condition (e.g., psychiatric disorder) that, in the opinion of the Investigator, may interfere with the subject's ability to comply with the study requirements or visit schedule
- Subjects with known hypersensitivity to TXA127
- Subjects with uncontrolled medical or psychiatric condition which would limit informed consent
- Subjects with a willing and appropriate HLA-matched related marrow donor
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: TXA127 300 mcg/kg/day
Treatment group 1 (300 mcg/kg/day) of a two-arm, dose-escalation pilot feasibility trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect.
|
Injection, 300 mcg/kg/day for 28 days
|
Experimental: TXA127 1000 mcg/kg/day
Treatment group 2 (1000 mcg/kg/day) of a two-arm, dose-escalation pilot feasibility trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect.
|
Injection, 1000 mcg/kg/day for 28 days
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Safety of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation
Zeitfenster: 100 days post-transplantation
|
The safety and tolerability profile of TXA127 will be provided by descriptively summarizing, at a minimum, the following outcomes: 1) number and proportion of patients with adverse events presented by preferred term, by system organ class (SOC), and by severity grade and relationship to TXA127, as assessed by the Investigator; 2) number and proportion of patients terminating TXA127 due to adverse events related to TXA127; 3) Day 100 treatment-related mortality (TRM) rate; 4) Day 100 mortality rate; 5) number of red blood cell and other blood component transfusions; 6) incidence of infection.
|
100 days post-transplantation
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Immunrekonstitution
Zeitfenster: 100 Tage nach der Transplantation
|
Die Immunrekonstitution wird über die Messung der peripheren Blutkonzentrationen von CD3+-, CD4+-, CD8+-, CD19+- und CD56+-Zellen (durchgeführt an den Studientagen 62 und 100) bewertet.
|
100 Tage nach der Transplantation
|
Incidence, duration, and severity grade of mucositis
Zeitfenster: 100 days post-transplantation
|
Incidence of mucositis is defined by the occurrence of least one adverse event with MedDRA preferred term that includes "mucositis" or "stomatitis".
The severity grade will be determined by NCI-CTCAE.
|
100 days post-transplantation
|
Platelet transfusion requirements
Zeitfenster: 100 days post-transplantation
|
Platelet transfusion requirements based on units of platelets transfused and days of platelet transfusions
|
100 days post-transplantation
|
Incidence, duration, and severity grade of acute graft-vs-host-disease (aGVHD)
Zeitfenster: 100 days post-transplantation
|
Incidence, severity and duration of aGVHD will be reported as a proportion (with 95% CIs) of subjects with Grade II-IV aGVHD.
All incidents of aGVHD will at a minimum be listed, with the severity and time course included.
|
100 days post-transplantation
|
Time to engraftment/recovery
Zeitfenster: 100 days post-transplantation
|
Time to neutrophil engraftment and platelet recovery
|
100 days post-transplantation
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Uday R Popat, MD, M.D. Anderson Cancer Center
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. Januar 2011
Primärer Abschluss (Tatsächlich)
1. Dezember 2020
Studienabschluss (Tatsächlich)
1. Dezember 2020
Studienanmeldedaten
Zuerst eingereicht
17. Februar 2011
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
17. Februar 2011
Zuerst gepostet (Schätzen)
21. Februar 2011
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
8. Dezember 2020
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
7. Dezember 2020
Zuletzt verifiziert
1. Dezember 2020
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Neubildungen
- Lymphoproliferative Erkrankungen
- Lymphatische Erkrankungen
- Immunproliferative Erkrankungen
- Erkrankungen des Knochenmarks
- Hämatologische Erkrankungen
- Myeloproliferative Erkrankungen
- Leukämie, lymphatisch
- Leukämie, B-Zell
- Lymphom
- Myelodysplastische Syndrome
- Leukämie
- Leukämie, Myeloid
- Leukämie, myeloisch, akut
- Vorläuferzelle lymphoblastische Leukämie-Lymphom
- Leukämie, lymphozytär, chronisch, B-Zell
- Leukämie, myeloische, chronische, BCR-ABL-positiv
- Antihypertensive Mittel
- Vasodilatator-Wirkstoffe
- Angiotensin I (1-7)
Andere Studien-ID-Nummern
- TXA127-2010-001
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur TXA127 300 mcg/kg/day
-
Janssen Pharmaceutical K.K.Abgeschlossen
-
MedImmune LLCAbgeschlossenChronischer lymphatischer Leukämie | Non-Hodgkin-LymphomVereinigte Staaten, Polen
-
Mayo ClinicRekrutierungSchmerzkontrolleVereinigte Staaten
-
Bausch Health Americas, Inc.AbgeschlossenRheumatoide ArthritisVereinigte Staaten
-
DBV TechnologiesAbgeschlossenLebensmittelallergieVereinigte Staaten, Kanada
-
Mylan Pharmaceuticals IncAbgeschlossenGesundVereinigte Staaten
-
Yale UniversityNational Institute on Drug Abuse (NIDA)AbgeschlossenNikotinabhängigkeitVereinigte Staaten
-
Cara Therapeutics, Inc.AbgeschlossenJuckreiz | Urämischer JuckreizVereinigte Staaten
-
Cara Therapeutics, Inc.Abgeschlossen
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH); Department of Health and Human ServicesAktiv, nicht rekrutierend